Sangamo Therapeutics, Inc. (0R1D.L)
USD 0.75
(2.51%)
USD 0.75
(2.51%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -45.32 Million USD | 55.3% |
| 2022 | 99.19 Million USD | -2.05% |
| 2021 | 101.26 Million USD | 262.14% |
| 2020 | -62.45 Million USD | -43.59% |
| 2019 | -43.49 Million USD | -43.01% |
| 2018 | -30.41 Million USD | -4.3% |
| 2017 | -29.16 Million USD | 36.92% |
| 2016 | -46.22 Million USD | -67.56% |
| 2015 | -27.58 Million USD | -153.72% |
| 2014 | -10.87 Million USD | 15.35% |
| 2013 | -12.84 Million USD | -27.77% |
| 2012 | -10.05 Million USD | -197.43% |
| 2011 | 10.31 Million USD | -50.4% |
| 2010 | 20.8 Million USD | -6.23% |
| 2009 | 22.18 Million USD | 37.08% |
| 2008 | 16.18 Million USD | 77.91% |
| 2007 | 9.09 Million USD | 15.38% |
| 2006 | 7.88 Million USD | 217.43% |
| 2005 | 2.48 Million USD | 88.9% |
| 2004 | 1.31 Million USD | -49.01% |
| 2003 | 2.57 Million USD | -40.62% |
| 2002 | 4.34 Million USD | -11.1% |
| 2001 | 4.88 Million USD | -43.62% |
| 2000 | 8.66 Million USD | 198.79% |
| 1999 | 2.9 Million USD | 42.3% |
| 1998 | 2.03 Million USD | 76.91% |
| 1997 | 1.15 Million USD | 82.28% |
| 1996 | 632 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -2.21 Million USD | -8.41% |
| 2024 Q1 | -2.04 Million USD | -117.55% |
| 2023 FY | 154.04 Million USD | 55.3% |
| 2023 Q2 | 2.57 Million USD | -98.33% |
| 2023 Q3 | -113 Thousand USD | -104.38% |
| 2023 Q4 | -940 Thousand USD | -731.86% |
| 2023 Q1 | 154.46 Million USD | 546.66% |
| 2022 Q3 | 23.41 Million USD | -11.64% |
| 2022 FY | 99.19 Million USD | -2.05% |
| 2022 Q1 | 25.39 Million USD | 0.7% |
| 2022 Q2 | 26.49 Million USD | 4.31% |
| 2022 Q4 | 23.88 Million USD | 2.03% |
| 2021 Q2 | -32.21 Million USD | -6.83% |
| 2021 Q1 | -30.15 Million USD | -13.54% |
| 2021 Q4 | 25.22 Million USD | 174.32% |
| 2021 Q3 | -33.93 Million USD | -5.34% |
| 2021 FY | 101.26 Million USD | 262.14% |
| 2020 Q2 | -19.97 Million USD | 29.69% |
| 2020 Q1 | -28.4 Million USD | -271.91% |
| 2020 Q4 | -26.55 Million USD | -312.87% |
| 2020 Q3 | 12.47 Million USD | 162.47% |
| 2020 FY | -62.45 Million USD | -43.59% |
| 2019 Q2 | -18.9 Million USD | 29.4% |
| 2019 Q4 | 16.52 Million USD | 215.3% |
| 2019 Q3 | -14.33 Million USD | 24.21% |
| 2019 FY | -43.49 Million USD | -43.01% |
| 2019 Q1 | -26.77 Million USD | -317.31% |
| 2018 Q2 | -7.83 Million USD | 28.15% |
| 2018 Q4 | -6.41 Million USD | -22.28% |
| 2018 FY | -30.41 Million USD | -4.3% |
| 2018 Q1 | -10.91 Million USD | -73.17% |
| 2018 Q3 | -5.24 Million USD | 33.05% |
| 2017 Q1 | -9.51 Million USD | -91.57% |
| 2017 Q2 | -6.73 Million USD | 29.27% |
| 2017 Q3 | -6.61 Million USD | 1.75% |
| 2017 Q4 | -6.3 Million USD | 4.73% |
| 2017 FY | -29.16 Million USD | 36.92% |
| 2016 Q3 | -14.18 Million USD | 9.95% |
| 2016 Q1 | -11.32 Million USD | -5.68% |
| 2016 FY | -46.22 Million USD | -67.56% |
| 2016 Q2 | -15.75 Million USD | -39.1% |
| 2016 Q4 | -4.96 Million USD | 64.98% |
| 2015 Q1 | -1.48 Million USD | -3717.95% |
| 2015 Q2 | -7.26 Million USD | -387.58% |
| 2015 FY | -27.58 Million USD | -153.72% |
| 2015 Q3 | -8.12 Million USD | -11.91% |
| 2015 Q4 | -10.71 Million USD | -31.88% |
| 2014 Q2 | -3.07 Million USD | 22.49% |
| 2014 FY | -10.87 Million USD | 15.35% |
| 2014 Q3 | -3.92 Million USD | -27.58% |
| 2014 Q4 | -39 Thousand USD | 99.01% |
| 2014 Q1 | -3.96 Million USD | -1.48% |
| 2013 Q1 | -3.59 Million USD | -140.27% |
| 2013 Q3 | -2.99 Million USD | -27.82% |
| 2013 Q4 | -3.9 Million USD | -30.47% |
| 2013 FY | -12.84 Million USD | -27.77% |
| 2013 Q2 | -2.34 Million USD | 34.83% |
| 2012 Q1 | 3.24 Million USD | -31.72% |
| 2012 Q2 | 4.57 Million USD | 41.09% |
| 2012 Q3 | -2.66 Million USD | -158.22% |
| 2012 Q4 | 8.93 Million USD | 435.41% |
| 2012 FY | -10.05 Million USD | -197.43% |
| 2011 Q1 | 2.2 Million USD | -53.08% |
| 2011 Q2 | 1.51 Million USD | -31.18% |
| 2011 Q3 | 1.85 Million USD | 22.66% |
| 2011 Q4 | 4.74 Million USD | 155.68% |
| 2011 FY | 10.31 Million USD | -50.4% |
| 2010 Q4 | 4.68 Million USD | 59.33% |
| 2010 Q1 | 6.64 Million USD | -35.08% |
| 2010 FY | 20.8 Million USD | -6.23% |
| 2010 Q2 | 6.52 Million USD | -1.85% |
| 2010 Q3 | 2.94 Million USD | -54.9% |
| 2009 Q4 | 10.24 Million USD | 152.06% |
| 2009 Q2 | 4.72 Million USD | 49.7% |
| 2009 Q1 | 3.15 Million USD | -53.8% |
| 2009 Q3 | 4.06 Million USD | -14.03% |
| 2009 FY | 22.18 Million USD | 37.08% |
| 2008 Q2 | 2.84 Million USD | 2.78% |
| 2008 FY | 16.18 Million USD | 77.91% |
| 2008 Q4 | 6.83 Million USD | 82.48% |
| 2008 Q3 | 3.74 Million USD | 31.77% |
| 2008 Q1 | 2.76 Million USD | -0.07% |
| 2007 Q3 | 2.32 Million USD | -10.02% |
| 2007 Q2 | 2.58 Million USD | 81.72% |
| 2007 Q1 | 1.42 Million USD | -35.16% |
| 2007 Q4 | 2.76 Million USD | 19.01% |
| 2007 FY | 9.09 Million USD | 15.38% |
| 2006 FY | 7.88 Million USD | 217.43% |
| 2006 Q3 | 1.77 Million USD | 0.11% |
| 2006 Q2 | 1.77 Million USD | -16.81% |
| 2006 Q1 | 2.13 Million USD | 52.9% |
| 2006 Q4 | 2.19 Million USD | 23.27% |
| 2005 Q3 | 412 Thousand USD | -1.44% |
| 2005 Q2 | 418 Thousand USD | 63.28% |
| 2005 Q1 | 256 Thousand USD | 28.0% |
| 2005 FY | 2.48 Million USD | 88.9% |
| 2005 Q4 | 1.39 Million USD | 239.08% |
| 2004 FY | 1.31 Million USD | -49.01% |
| 2004 Q1 | 811 Thousand USD | -19.14% |
| 2004 Q2 | 132 Thousand USD | -83.72% |
| 2004 Q3 | 172 Thousand USD | 30.3% |
| 2004 Q4 | 200 Thousand USD | 16.28% |
| 2003 FY | 2.57 Million USD | -40.62% |
| 2003 Q1 | 551 Thousand USD | -77.64% |
| 2003 Q4 | 1 Million USD | 97.83% |
| 2003 Q3 | 507 Thousand USD | -2.12% |
| 2003 Q2 | 518 Thousand USD | -5.99% |
| 2002 Q4 | 2.46 Million USD | 143.48% |
| 2002 FY | 4.34 Million USD | -11.1% |
| 2002 Q3 | 1.01 Million USD | 176.5% |
| 2002 Q2 | 366 Thousand USD | -26.95% |
| 2002 Q1 | 501 Thousand USD | -76.85% |
| 2001 Q1 | 634 Thousand USD | -89.49% |
| 2001 FY | 4.88 Million USD | -43.62% |
| 2001 Q4 | 2.16 Million USD | 192.83% |
| 2001 Q3 | 739 Thousand USD | -45.18% |
| 2001 Q2 | 1.34 Million USD | 112.62% |
| 2000 Q2 | 837 Thousand USD | -50.59% |
| 2000 Q1 | 1.69 Million USD | 0.0% |
| 2000 FY | 8.66 Million USD | 198.79% |
| 2000 Q4 | 6.03 Million USD | 545.72% |
| 2000 Q3 | 934 Thousand USD | 11.59% |
| 1999 FY | 2.9 Million USD | 42.3% |
| 1998 FY | 2.03 Million USD | 76.91% |
| 1997 FY | 1.15 Million USD | 82.28% |
| 1996 FY | 632 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 54.46% |
| Dynavax Technologies Corporation | 182.11 Million USD | 124.888% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 406.374% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.171% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 108.654% |
| Perrigo Company plc | 1.68 Billion USD | 102.697% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | -14380.831% |
| Illumina, Inc. | 2.74 Billion USD | 101.652% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.298% |
| Nektar Therapeutics | 53.47 Million USD | 184.754% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | -373.814% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 100.865% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 551.354% |
| Unity Biotechnology, Inc. | -19.69 Million USD | -130.088% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 102.38% |
| Waters Corporation | 1.76 Billion USD | 102.574% |
| Biogen Inc. | 7.3 Billion USD | 100.621% |
| Adicet Bio, Inc. | -6.09 Million USD | -643.276% |
| Evolus, Inc. | 140.52 Million USD | 132.254% |
| bluebird bio, Inc. | -4.03 Million USD | -1024.69% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 46.812% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 162.032% |
| FibroGen, Inc. | 128.9 Million USD | 135.162% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 101.308% |
| Homology Medicines, Inc. | -7.22 Million USD | -526.989% |
| Geron Corporation | -123.5 Million USD | 63.3% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 102.986% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | -45.423% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 112.52% |
| Myriad Genetics, Inc. | 476.4 Million USD | 109.514% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.401% |
| OPKO Health, Inc. | 318.12 Million USD | 114.247% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -15422.26% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 88.634% |
| Zoetis Inc. | 5.83 Billion USD | 100.777% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 15108.278% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 102.09% |
| Exelixis, Inc. | 1.75 Billion USD | 102.579% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.527% |
| uniQure N.V. | 2.21 Million USD | 2146.275% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -14858.746% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 118.535% |
| Verastem, Inc. | -62 Thousand USD | -73004.839% |
| Imunon, Inc. | -720 Thousand USD | -6195.095% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 105.822% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 104.147% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 102.453% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 109.524% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 107.117% |
| TG Therapeutics, Inc. | 219.1 Million USD | 120.686% |
| Blueprint Medicines Corporation | 236.58 Million USD | 119.158% |
| Insmed Incorporated | 239.63 Million USD | 118.914% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 361.707% |
| Incyte Corporation | 3.44 Billion USD | 101.317% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 113.18% |